Skip to content

Savara SVRA Investment Purchases

Investment Purchases at other companies

Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$58.3M+692%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$43.41M+2,106%
United Therapeutics logo
United TherapeuticsUTHR
$701.7M+1.4%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$15.01M-90.4%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$0-100%
Moderna logo
ModernaMRNA
$1.35B-23.6%

Other financials

Income statement

See full
Revenue-
Operating income-$39.0M-37.1%
Net income-$37.3M-40.0%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$38.8M+98.4%
Total debt$30.1M+1.8%
Total equity$176.0M+19.1%
Total assets$221.6M+17.1%

Cash flow

See full
Operating cash flow-$33.0M-21.5%
CapEx$54.0K+1,700%
Free cash flow-$33.1M-21.7%

Valuation

See full
Market cap$1.24B+247%
Enterprise value$1.23B+235%
P/S4,808.2×

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-80%+4.7pp
Debt / equity0.2×0.0×
Current ratio13.5×-1.4×

Where this comes from

Reported directly by Savara in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt.

The official record: Savara’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Savara's investment purchases.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Savara's investment purchases?
Savara (SVRA) reported investment purchases of $127.24M in Q4 2025.
How has Savara's investment purchases changed year-over-year?
Savara's investment purchases increased by 296.8% year-over-year, from $32.06M to $127.24M.
What is the long-term trend for Savara's investment purchases?
Over 3 years (2021 to 2025), Savara's investment purchases has grown at a 8.4% compound annual growth rate (CAGR), from $161.07M to $204.9M.
What does investment purchases mean?
Cash spent purchasing investment securities across all categories.